Diphtheria (D), Tetanus (T), Pertussis (Acellular, Component) (Pa), Hepatitis B (Rdna) (Hbv), Poliomyelitis (Inactivated) (Ipv) And Haemophilus Influenzae Type-B (Hib) Conjugate Vaccine(Glaxosmithkline Plc)

The study provides a descriptive understanding of the toxic effect of heavy metal chromium on the hematological, biochemical, and digestive enzyme profiles in the fingerlings of Labeo rohita. The 96-h LC₅₀ of hexavalent chromium was found to be 15.76 mg/L. Further, the toxicity study was conducted with four different sub-lethal concentrations of 96-h LC₅₀ viz. 1/40th, 1/20th, 1/10th, and 1/5th respectively. The blood samples from the control and treated groups exposed to different concentrations were examined for various physiological parameters. The obtained data showed that, with the increase in sub-lethal concentration, a significant decrease (p < 0.05) in red blood cell (RBCs), hemoglobin (Hb), and hematocrit (Hct) was observed, while total white blood cell (WBCs), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) increased significantly (p < 0.05) in all the treatments. Fishes exposed to chromium for 30 days responded by becoming hyperglycemic, hyperproteineric, and hypoalbuminemia with a gradual rise in concentrations. Alteration in the intestinal digestive enzyme profiles was also observed after 30 days of study. The activity of protease (89.76%), and amylase (41.88%) decreased in the intestine with the highest concentration compared to the control. Conversely, compared to the control, the highest concentration resulted in an increase (146%) in lipase activity. Overall, this study has greatly enhanced our comprehension of the impact of chromium toxicity on various hematological, biochemical, and digestive enzyme parameters in Labeo rohita.

Vaccine co-administration is a useful strategy for improving vaccine coverage and adherence. In Italy, an update to the national immunization program (NIP) in 2023 included recommendations for co-administration of pediatric vaccines, including the four-component vaccine for meningococcus B (4CMenB), pneumococcal conjugate vaccine (PCV), hexavalent vaccines, and oral rotavirus vaccines. Safety is a major concern when considering vaccine co-administration; therefore, a literature review of the available evidence on 4CMenB co-administration with PCV, hexavalent/pentavalent, and rotavirus vaccines was performed. Of 763 publications screened, two studies were reviewed that reported safety data on 4CMenB co-administration with PCV, hexavalent/pentavalent, and rotavirus vaccines in infants aged 0-24 months. Overall, these studies supported that there were no significant safety signals when co-administering 4CMenB with PCV, hexavalent/pentavalent, and rotavirus vaccines, compared with individual vaccination. This review provides key insights for healthcare professionals on the tolerability of co-administering 4CMenB with routine vaccines.